Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Argus Health
Chinese Patent Office
Express Scripts

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091510

« Back to Dashboard
NDA 091510 describes CARBOPLATIN, which is a drug marketed by Pliva, Mylan Labs Ltd, Hospira, Gland Pharma Ltd, Sun Pharma Global, Pliva Lachema, Actavis Totowa, Fresenius Kabi Oncol, Fresenius Kabi Usa, Teva Pharms Usa, West-ward Pharms Int, Sandoz, Cipla Ltd, Watson Labs Teva, Akorn, Pharmachemie Bv, Accord Hlthcare, Sandoz Inc, Ingenus Pharms Llc, Sanja Pharms Co, Teva Parenteral, Nanjing King-friend, and Mylan Institutional, and is included in thirty-three NDAs. It is available from eleven suppliers. Additional details are available on the CARBOPLATIN profile page.

The generic ingredient in CARBOPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the carboplatin profile page.

Summary for NDA: 091510

Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength50MG/VIAL
Approval Date:May 29, 2012TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength150MG/VIAL
Approval Date:May 29, 2012TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength450MG/VIAL
Approval Date:May 29, 2012TE:RLD:No

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Queensland Health
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus